Portable, Low-cost Hardware for De-centralized COVID-19 Diagnostics for Canada, Colombia and Ecuador
- Funded by International Development Research Centre (IDRC)
- Total publications:1 publications
Grant number: 109547
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$336,319.76Funder
International Development Research Centre (IDRC)Principal Investigator
Varsovia Enid Cevallos, Camila Gonzalez, Keith Ian PardeeResearch Location
Canada, ColombiaLead Research Institution
University of Toronto Biomolecular SciencesResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Here we propose to develop and demonstrate the hardware and molecular tools needed for high-capacity de-centralized COVID-19 diagnostics in Canada, Colombia and Ecuador. We will do this by adapting our portable plate reader, called PLUM, for distributed deployment of two key diagnostic modalities using our patient validated tests. 1) A rapid molecular SARS-CoV-2 diagnostic (RT-LAMP, 15 min) to prevent a resurgence of infection as our communities begin to reduce lockdown restrictions. 2) Serological testing to determine population antibody-levels and allow for strategic use of precious, future vaccine stocks. To bring these diagnostics assays (96 or 384 well plate) out of the laboratory setting and to the point-of-need, we will adapt the PLUM reader to provide the high-temperature incubation (65 C) needed for RT-LAMP. PLUM will also be augmented with purpose-built software and training materials to enable the use of diagnostics by users in the field (e.g. health care workers). This will include automated software for guidance on sample collection, running the assays, data analysis and secure data sharing to public health networks. The RT-LAMP assay, which has already been extensively tested with SARS-CoV-2 patient samples, will be augmented with new safeguard features to prevent false negative results and adapted to allow for RNA extraction-free use. The COVID-19 serological assay has also already been extensively validated with SARS-CoV-2 patient samples and here will be optimized for use in PLUM. Implementation and testing of this de-centralized diagnostic capacity will be performed at small businesses in Canada, and with hospital workers and remote populations in Colombia and Ecuador. Taken together, this proposed project combines a strong technical solutions with patient trials outside of conventional laboratory settings and will enable the development of the crucial de-centralized COVID-19 testing capacity needed for recovery from the pandemic.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC